Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.61 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7907439 | 0.95 | MAOB (0.56) | MAOBFFAR4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21924287 | 0.94 | MAOB (0.58) | MAOBFFAR4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3191667 | 0.94 | MAOB (0.58) | MAOBFFAR4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1763456 | 0.93 | MAOB (0.57) | MAOBFFAR4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3201763 | 0.93 | MAOB (0.57) | MAOBFFAR4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11557673 | 0.93 | KDM4E (0.60) | MAOBFFAR4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7911112 | 0.92 | MAOB (0.57) | MAOBFFAR4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7910894 | 0.92 | FFAR4 (0.65) | MAOBFFAR4LMNAKMT2ANR4A2 | |
| SCHEMBL7910948 | 0.92 | MAOB (0.57) | MAOBFFAR4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7909189 | 0.92 | MAOB (0.53) | MAOBFFAR4NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710462-B1 | BRARTEMICIN ANALOGUES | VICTORIA LINK LTD (NZ) | 2026-05-13 | — | — | EP | disclosed |
| US-20230139366-A1 | BRARTEMICIN ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2023-05-04 | — | — | US | disclosed |
| US-20230139366-A1 | BRARTEMICIN ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2023-05-04 | — | — | US | disclosed |
| US-11510980-B2 | Brartemicin analogues | VICTORIA LINK LTD. (NZ) | 2022-11-29 | — | — | US | disclosed |
| US-11236053-B2 | NADPH oxidase inhibitors and uses thereof | EMORY UNIVERSITY (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210177965-A1 | BRARTEMICIN ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2021-06-17 | — | — | US | disclosed |
| US-20210177965-A1 | BRARTEMICIN ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2021-06-17 | — | — | US | disclosed |
| EP-3710462-A1 | BRARTEMICIN ANALOGUES | Victoria Link Limited (NZ) | 2020-09-23 | — | — | EP | disclosed |
| US-20200270214-A1 | NADPH Oxidase Inhibitors and Uses Thereof | UNIV EMORY (US) | 2020-08-27 | — | — | US | disclosed |
| WO-2019023448-A1 | NADPH OXIDASE INHIBITORS AND USES THEREOF | EMORY UNIVERSITY (US) | 2019-01-31 | — | — | WO | disclosed |
| EP-2081891-A2 | PHARMACEUTICAL COMPOUNDS HAVING HSP90 INHIBITORY OR MODULATING ACTIVITY | Astex Therapeutics Limited (GB) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008044027-A2 | PHARMACEUTICAL COMPOUNDS HAVING HSP90 INHIBITORY OR MODULATING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139366-A1 | BRARTEMICIN ANALOGUES | RXFP1, RXFP2, RXFP4 | MAOB 4572/4885FFAR4 627/4885NPC1 4100/4885 |
| US-20200270214-A1 | NADPH Oxidase Inhibitors and Uses Thereof | NOX1, NOX3, NOX5 | MAOB 138/4885FFAR4 1596/4885NPC1 2534/4885 |
| US-20210177965-A1 | BRARTEMICIN ANALOGUES | RXFP1, RXFP2, CMKLR1 | MAOB 4537/4885FFAR4 735/4885NPC1 3983/4885 |
| US-11236053-B2 | NADPH oxidase inhibitors and uses thereof | NOX1, NOX3, NOX5 | MAOB 138/4885FFAR4 1596/4885NPC1 2534/4885 |
| US-11510980-B2 | Brartemicin analogues | RXFP1, RXFP2, CMKLR1 | MAOB 4537/4885FFAR4 735/4885NPC1 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.